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Abstract
Background
In 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) set the 90-90-90 tar-
gets: that 90% of people living with HIV know their HIV status, that 90% of those who know
their HIV-positive status are on antiretroviral therapy (ART), and that 90% of those on treat-
ment are virally suppressed. The aim was to reach these targets by 2020. We assessed the
feasibility of achieving the first two targets, and the corresponding 81% ART coverage tar-
get, as part of the HIV Prevention Trials Network (HPTN) 071 Population Effects of Antire-
troviral Therapy to Reduce HIV Transmission (PopART) community-randomized trial.
Methods and findings
The study population was individuals aged�15 years living in 14 urban and peri-urban
“PopART intervention” communities in Zambia and South Africa (SA), with a total population
of approximately 600,000 and approximately 15% adult HIV prevalence. Community HIV
care providers (CHiPs) delivered the PopART intervention during 2014–2017. This was a
combination HIV prevention package including universal home-based HIV testing, referral
of HIV-positive individuals to government HIV clinic services that offered universal ART
(Arm A) or ART according to national guidelines (Arm B), and revisits to HIV-positive individ-
uals to support linkage to HIV care and retention on ART. The intervention was delivered in
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gender, age group, and participation and residency
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that the ethics committees approved specifies that
intervention data can only be shared in aggregate
3 “rounds,” each about 15 months long, during which CHiPs visited all households and
aimed to contact all individuals aged�15 years at least once.
In Arm A in Round 3 (R3), 67% (41,332/61,402) of men and 86% (56,345/65,896) of
women in Zambia and 56% (17,813/32,095) of men and 71% (24,461/34,514) of women in
SA participated in the intervention, among 193,907 residents aged�15 years. Following
participation, HIV status was known by 90% of men and women in Zambia and by 78% of
men and 85% of women in SA. The median time from CHiP referral of HIV-positive individu-
als to ART initiation was approximately 3 months. By the end of R3, an estimated 95% of
HIV-positive women and 85% of HIV-positive men knew their HIV status, and among these
individuals, approximately 90% of women and approximately 85% of men were on ART.
ART coverage among all HIV-positive individuals was approximately 85% in women and
approximately 75% in men, up from about 45% at the start of the study. ART coverage was
lowest among men aged 18 to 34 and women aged 15 to 24 years, and among mobile indi-
viduals/in-migrants. Findings from Arm B were similar. The main limitations to our study
were that estimates of testing and treatment coverage among men relied on considerable
extrapolation because, in each round, approximately one-third of men did not participate in
the PopART intervention; that our findings are for a service delivery model that was rela-
tively intensive; and that we did not have comparable data from the 7 “standard-of-care”
(Arm C) communities.
Conclusions
Our study showed that very high HIV testing and treatment coverage can be achieved
through persistent delivery of universal testing, facilitated linkage to HIV care, and universal
treatment services. The ART coverage target of 81% was achieved overall, after 4 years of
delivery of the PopART intervention, though important gaps remained among men and
young people. Our findings are consistent with previously reported findings from southern
and east Africa, extending their generalisability to urban settings with high rates of in-migra-
tion and mobility and to Zambia and SA.
Trial registration
ClinicalTrials.gov NCT01900977
Author summary
Why was this study done?
• The HIV Prevention Trials Network (HPTN) 071 Population Effects of Antiretroviral
Therapy to Reduce HIV Transmission (PopART) trial aimed to establish whether uni-
versal testing and universal treatment for HIV could reduce population-level HIV inci-
dence in a generalised HIV epidemic.
• In 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) set targets that,
by 2020, 90% of people living with HIV know their HIV status, that 90% of those who
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know their HIV-positive status are on antiretroviral therapy (ART), and that 90% of
those on treatment are virally suppressed (the 90-90-90 targets).
• We assessed the feasibility of achieving these targets as part of the HPTN 071 (PopART)
community-randomised trial.
• The study population was individuals aged�15 years living in 14 urban and peri-urban
“PopART” intervention communities in Zambia and the Western Cape of South Africa
(SA), with a total population of approximately 600,000 and HIV prevalence of around
15%.
What did the researchers do and find?
• Community HIV care providers (CHiPs) delivered the PopART intervention during
2014–2017 inclusive. This was a combination HIV prevention package including uni-
versal home-based HIV testing, referral of HIV-positive individuals to government HIV
clinic services that offered universal ART (Arm A, 7 communities) or ART according to
national guidelines (Arm B, 7 communities), and revisits to HIV-positive individuals to
support linkage to HIV care and retention on ART.
• High levels of HIV testing and treatment coverage were achieved in communities that
received the PopART intervention, especially among women. After 4 years, approxi-
mately 95% of HIV-positive women and approximately 85% of HIV-positive men knew
their HIV status, up from about 55% at the start of the intervention. Among individuals
who knew their HIV-positive status after 4 years, approximately 90% of women and
approximately 85% of men were on ART, up from about 80% at the start of the interven-
tion. In the total HIV-positive population—both men and women—the cumulative 90–
90 target of 81% ART coverage was met, up from around 45% at the start of the study.
Viral suppression among individuals who were taking ART was high, at around 90% in
Zambian study communities and around 80%–90% in SA study communities.
• Testing and treatment coverage increased in each intervention round, but progress was
slowed by high rates of mobility and in-migration among both men and women. At the
start of a round of intervention, mobile individuals and in-migrants had lower knowl-
edge of HIV-positive status and ART coverage than “stable” residents. Progress was also
slowed by the relative difficulty of contacting men at home, which persisted throughout
the study.
• The main remaining gap in coverage against the first and second of the 90-90-90 targets
after 4 years of intervention was among men aged 18–34 years and women aged 15–24
years. This reflected fewer prior opportunities for facility-based HIV testing, relatively
high HIV incidence compared with HIV prevalence, and relatively high mobility and
in-migration rates. Participation in the PopART intervention and uptake of HIV testing
were similar to or higher among younger individuals compared with those aged 35–54
years.
What do these findings mean?
• Very high HIV testing and treatment coverage can be achieved through persistent deliv-
ery of universal testing, facilitated linkage to HIV care, and universal treatment services.
PLOS MEDICINE HIV testing and treatment coverage after 4 years of the HPTN 071 trial
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003067 April 2, 2020 3 / 30
• Our findings are consistent with previously reported findings from southern and east
Africa, extending their generalisability to urban settings with high rates of in-migration
and mobility and to Zambia and SA.
Introduction
In 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) set the so-called “90-
90-90” global targets: that 90% of HIV-positive individuals know their HIV-positive status,
90% of those who know their HIV-positive status are on antiretroviral therapy (ART), and
90% of those taking ART are virally suppressed [1]. The targets were set for 2020, with the aim
of reducing the number of new HIV infections among adults from approximately 2 million in
2015 to approximately 500,000 per year in 2020. The 90-90-90 targets correspond cumulatively
to 81% of HIV-positive individuals being on ART and 73% being virally suppressed.
By 2017–2018, data from nationally representative Population-based HIV Impact Assess-
ment (PHIA) surveys across 10 countries in sub-Saharan Africa showed substantial progress
toward the cumulative 90-90-90 target in 7 countries [2,3]. The cumulative target had been
met in Namibia, was close to being met in eSwatini and Malawi, and was approximately 10%
below target in Zambia, Zimbabwe, Lesotho, and Uganda. Progress fell short of the target in
Tanzania, Cameroon, and Ivory Coast. Across 9 of the 10 countries, both the percentage on
ART among individuals who knew their HIV-positive status (“second 90”) and the percentage
with viral suppression among those taking ART (“third 90”) was on or close to target, overall
and for both men and women [2]. The key gap that remained to be closed was for the percent-
age of HIV-positive individuals who knew their HIV-positive status (“first 90”), with the gap
being wider for men than for women and wider for younger than older individuals.
Four cluster-randomised trials (CRTs) of the effect of combination HIV prevention pack-
ages, which included universal HIV testing and universal treatment alongside pre-existing ser-
vice provision, on HIV incidence have also provided evidence about coverage against the 90-
90-90 targets. These are the ANRS 12249 Treatment as Prevention (TasP) trial in South Africa
(SA), the Sustainable East Africa Research in Community Health (SEARCH) trial in Uganda
and Kenya, the Botswana Combination Prevention Project (BCPP)/YaTsie trial in Botswana,
and the HIV Prevention Trials Network (HPTN) 071 Population Effects of Antiretroviral
Therapy to Reduce HIV Transmission (PopART) trial in Zambia and the Western Cape of SA.
At study end, after 3 years of intervention, the first and second 90 targets and the cumulative
90-90-90 target of 73% were achieved in the SEARCH trial, and in the BCPP/YaTsie trial 95-
95-95 was reached [4,5]. In contrast, in the ANRS 12249 TasP trial coverage against the second
90 target remained relatively low at study end, after 2 years of intervention [6].
Previously, we reported the progress of the PopART universal testing and treatment (UTT)
intervention toward the 90-90-90 targets after the first 2 years of the study (2014–2016). At
that time, the first 90 target was close to being met, and an estimated approximately 80% of
HIV-positive individuals who knew their HIV-positive status were on ART [7]. Challenges to
reaching the first and second 90 targets included the following: difficulties in contacting men;
high rates of mobility and in-migration to study communities that meant that, in each year, a
considerable proportion of the population was newly resident and had lower testing-and-treat-
ment coverage than previously resident individuals; that approximately 20% of individuals
who participated in the wider intervention declined HIV testing; and slower-than-targeted
linkage to HIV care [7,8].
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In this paper, we report on progress toward reaching the first and second 90 targets after 4
years of delivering the PopART UTT intervention (2014–2017) and the extent to which it was
possible to close the gaps in coverage that were identified during 2014–2016 with more time,
accumulated experience, and new approaches. We also compare testing and treatment cover-
age between the 2 intervention trial arms of the PopART study to provide insight into the pri-
mary finding of the trial that HIV incidence in the PopART UTT intervention trial arm was
around 10% lower than in the standard-of-care trial arm, but it was around 30% lower in the
“intermediate” PopART intervention trial arm [9].
Methods
Setting and trial design
The study population consisted of individuals aged�15 years living in the 14 intervention com-
munities of the HPTN 071 (PopART) CRT, 8 in Zambia and 6 in the Western Cape of SA. The
communities were urban or peri-urban, with a total population across the 14 communities of
approximately 600,000 [10]. HIV prevalence was around 10% in men and around 20% in women,
with peak HIV prevalence among men aged 40 to 49 years and women aged 35 to 44 years [7].
Seven communities were randomised to receive the “full” PopART intervention, including UTT
(Arm A, described below), and 7 communities were randomised to receive the “intermediate”
PopART intervention, with universal testing but with ART offered according to national guide-
lines (Arm B). Seven communities were randomised to receive standard of care (the control, Arm
C), and the trial design is summarised in Fig 1. The primary outcome of the study (HIV incidence)
and secondary outcomes were measured in a population cohort study, with sample size chosen to
have good study power to make comparisons between both of Arms A and B with Arm C [9,10].
PopART intervention
Community HIV care providers (CHiPs) delivered the PopART intervention during 2014–
2017 inclusive. This consisted of offering universal home-based HIV testing, referral of HIV-
positive individuals to government HIV clinic services that offered universal ART (Arm A) or
Fig 1. Summary of the HPTN 071 (PopART) trial design. CD4, cluster of differentiation 4; ART, antiretroviral
therapy.
https://doi.org/10.1371/journal.pmed.1003067.g001
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ART according to national guidelines (Arm B), and revisits to HIV-positive individuals to sup-
port linkage to HIV care and retention on ART, as well as various other services that together
made up a combination HIV prevention package, as described previously [7,11]. Arm B com-
munities transitioned to offering universal treatment in mid-2016, so service delivery was the
same as in Arm A for the last 18 months of the intervention.
Before the start of the PopART intervention, each intervention community was divided
into “zones” containing approximately 500 households. CHiPs worked in teams of 2, with
each team responsible for one zone. They delivered the intervention in “rounds,” during
which they visited all households, offered to explain the intervention, and asked permission to
enumerate (list) all household members. The first round (Round 1 [R1]) was November 2013
to June 2015, the second (Round 2 [R2]) was June 2015 to October 2016, and the third (Round
3 [R3]) was October 2016 to December 2017. Within each round, CHiPs aimed to contact all
individuals aged�15 years (R2–R3) or�18 years (R1) at least once to offer them intervention
services. No “incentives” to participation were provided.
During R2–R3, new strategies were implemented to try to increase participation, HIV test-
ing uptake, and linkage to HIV care, contributing to improvements across this cascade [7]. In
some zones, CHiPs periodically supplemented their household visits with “zonal campaigns”
during which they offered services in a non-household setting, such as at markets and trans-
port hubs [12]; in most zones, they worked shifts early and late in the day and on weekends
[13]. In Zambia in February 2017, the novel option of HIV self-testing was introduced to half
of the CHiP zones in 2 Arm A and 2 Arm B communities, in a nested randomised trial. Fol-
lowing evidence that this increased testing uptake among men [14], the option to self-test was
rolled out to all CHiP zones in Zambia during July–December 2017. For individuals who had
been referred but not yet linked to care, or who had dropped out of care, household follow-up
visits and/or phone calls were made to provide additional counselling and to offer to accom-
pany an individual to the clinic. Coordination between the CHiPs and the clinic was improved,
and various clinic improvements were made.
Data collection, outcomes, and explanatory variables
CHiPs recorded information on electronic registers, as described elsewhere [7,11]. For each
round, individuals were considered to have participated in the intervention if they verbally
consented to participate and health counselling was done. They were “known HIV positive” if
during that round they either self-reported that they were HIV positive or accepted the offer of
HIV testing and tested HIV positive. They were considered to “know their HIV status” if they
either self-reported HIV positive, tested for HIV with CHiPs, or self-reported that they had
tested HIV negative in the last 3 months. For all individuals who were “known HIV positive,”
CHiPs were expected to collect updated information at follow-up visits about whether an indi-
vidual was still resident in the zone, and if the individual was contacted, they collected self-
reported information on ART initiation and retention.
The main outcomes were participation in the intervention, knowledge of HIV status
among those who participated, the percentage of participants who were known by the CHiPs
to be HIV positive, estimates of coverage against the first and second 90 targets among partici-
pants and with extrapolation to the total population, and estimates of the time from CHiP
referral to ART initiation. These outcomes were prespecified in the HPTN 071 (PopART) sta-
tistical analysis plan [15]; they were summarised throughout the study to monitor intervention
delivery and were regularly reviewed by the study’s Data Safety and Monitoring Board
(DSMB). Explanatory variables were trial arm, country, round of intervention, sex, age group,
and residency/participation in previous rounds of intervention.
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Estimation of the number of HIV-positive individuals in the population
and coverage against the first and second 90 targets: “Central” estimates
and sensitivity analyses
Methods for estimating the number of HIV-positive individuals in the total population (both
participants and nonparticipants) and associated coverage against the first and second 90 tar-
gets have been described in detail previously [7,16]. They were also set out in the HPTN 071
statistical analysis plan [15] and are summarized in Box 1.
Box 1. Summary of methods used to estimate coverage against the
first two of the UNAIDS 90-90-90 targets
Among individuals who participated in the intervention in a particular round, we esti-
mated the number of HIV-positive individuals as the number who were “known HIV
positive” plus an estimated number among those whose HIV status was not known to
CHiPs, assuming that HIV prevalence in the latter group was the same as among those
who tested for HIV. We then calculated:
1. the proportion of HIV-positive individuals who knew their HIV-positive status
immediately before the household visit of that round as the total who self-reported
they were HIV-positive, divided by the estimated number of HIV-positive
individuals;
2. the proportion who knew their HIV-positive status immediately after the house-
hold visit of that round as the total who were known by the CHiPs to be HIV posi-
tive following the round (self-reported HIV positive or tested HIV positive with
CHiPs), divided by the estimated number of HIV-positive individuals;
3. the proportion who were on ART immediately after the household visit of that
round, among those who knew their HIV-positive status, as the total who self-
reported that they were on ART divided by the number who were known by the
CHiPs to be HIV positive following the round; and
4. the proportion who were on ART by the end of the round, among those who knew
their HIV-positive status, as the total who self-reported that they were on ART at
the last CHiP visit made during the round, divided by the number who were
known by the CHiPs to be HIV positive and who remained resident in the same
zone of the community according to the last information collected during the
round.
For “central” estimates of coverage, we extrapolated to the total population (including
individuals who did not participate in the intervention in a particular round) by assum-
ing that HIV prevalence was the same in nonparticipants and participants and that
knowledge of HIV-positive status and ART uptake among nonparticipants of a round
was the same as among participants immediately before they were visited by CHiPs in
that round. In sensitivity analysis, we varied 6 key values around the “central” assump-
tions: HIV prevalence, knowledge of HIV-positive status, and ART uptake, separately
for (i) participants whose HIV status was unknown to CHiPs and (ii) nonparticipants.
In total, we considered 486 scenarios (2 × 3 × 3 × 3 × 3 × 3, in order of the 6 values
above).
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Estimation of the time from CHiP referral to ART initiation
For each round, we used the Kaplan-Meier “time-to-event” method to estimate the time from first
CHiP referral in that round to self-reported ART initiation, among individuals who self-reported they
were not on ART on the date of referral. We used data on follow-up visits up to the end of the subse-
quent round of intervention, giving the potential for all referred individuals to be followed up for at
least 12 months after referral. For individuals who were not known to have started ART, we censored
their follow-up on the date of the last visit at which they were contacted by CHiPs in person.
Focus of results presented
All analyses were done separately for each trial arm, country, and round of intervention, with a
focus on findings from R3 and on placing those findings in the context of findings from R1–
R2. For SA, findings from R1–R2 are presented only for estimates of the time from CHiP refer-
ral to ART initiation, due to data collection challenges in R1–R2 [7]. We focus primarily on
findings from the 7 Arm A communities that received the PopART UTT intervention during
2014–2017. We follow this with a summary and synthesis of whether the findings were similar
or different in Arm B communities, in which universal treatment was offered from mid-2016
following a change to national guidelines on ART eligibility.
Estimates of the “third 90” from the HPTN 071 (PopART) population
cohort study
From November 2013 to March 2015, a randomly selected cohort of adults aged 18 to 44 years
was enrolled into the HPTN 071 (PopART) population cohort study, to measure the primary
outcome of HIV incidence as well as secondary outcomes including viral suppression among
HIV-positive individuals [9]. This was a research study, with written informed consent, with
annual follow-up for 3 years and a request for collection of a venous blood sample at each fol-
low-up visit. At the 24-month follow-up, conducted from approximately mid-2016 to approxi-
mately mid-2017, viral load was measured in all HIV-positive individuals, with viral load
testing conducted at the HPTN Laboratory Centre. In the absence of data on viral suppression
from the intervention service delivery data, we used viral load data from the 24-month follow-
up of the population cohort study to provide estimates of the “third 90,” i.e., the percentage of
HIV-positive individuals with viral suppression, among those on ART. The denominator for
our analysis was individuals who tested HIV-positive on laboratory HIV testing of a venous
blood sample and had viral load testing done and—as part of the 24-month follow-up inter-
view—self-reported that they had taken ART during the previous month.
Ethical considerations
The study was approved by the ethics committees of the London School of Hygiene & Tropical
Medicine, the University of Zambia, and Stellenbosch University. Individuals gave informed
All estimates were calculated within strata defined by all combinations of trial arm,
round, community, sex, and age group; for Zambia, estimates for R2–R3 were also strati-
fied on participation, residency, and HIV status in previous rounds.
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verbal consent to participation in the intervention, and informed written or witnessed consent
for HIV testing.
Results
Arm A, R3: Households visited and enumerated, total individuals
enumerated, and population structure
CHiPs visited 75,472 households during R3, approximately 100% of the total. Consent to enu-
meration of household members was given by 94% of households, and 193,907 individuals
aged�15 years were recorded. Among individuals aged�15 years, approximately 50% were
aged<30 years, and in Zambian communities about one-third were newly resident in the area
of the community in which they were living in R3—consistent with R2 findings of high levels
of mobility within the communities and in-migration from outside them (Table 1).
Arm A: Participation in intervention
During R3, in both Zambian and SA communities it remained challenging for CHiPs to con-
tact men at home. However, in Zambian communities the percentage of men who participated
in the intervention in R3 was higher than in R2 across all age groups (Fig 2), with an overall
figure of 67% (41,332/61,402) in R3 compared with 62% in R2. Participation was highest
among men who had participated in R1 and/or R2 and much higher than among men who
were previously resident but did not participate in R1 or R2 (S1 Fig). Among all men who
were resident in R3, 78% participated in one of R1–R3. The percentage of men who
Table 1. Arm A: Population structure among individuals enumerated as a household member in R3.
Zambian communities SA communities
Individual characteristic Men Women Men Women
(N = 61,402) (N = 65,896) (N = 32,095) (N = 34,514)
Age group (years) n % n % n % n %
15–17 5,728 9.3 6,608 10.0 1,910 5.9 2,273 6.6
18–19 4,567 7.4 5,455 8.3 1,646 5.1 1,902 5.5
20–24 11,386 18.5 14,463 21.9 5,309 16.5 6,079 17.6
25–29 9,677 15.8 10,541 16.0 5,425 16.9 5,902 17.1
30–34 8,223 13.4 8,059 12.2 5,133 16.0 5,116 14.8
35–39 6,819 11.1 6,149 9.3 3,821 11.9 3,736 10.8
40–44 5,280 8.6 4,404 6.7 3,032 9.4 3,059 8.9
45–49 3,336 5.4 2,797 4.2 2,063 6.4 2,243 6.5
50–54 2,057 3.3 2,413 3.7 1,664 5.2 1,783 5.2
55–59 1,419 2.3 1,678 2.5 985 3.1 1,050 3.0
60–64 1,010 1.6 1,306 2.0 594 1.8 614 1.8
�65 1,900 3.1 2,023 3.1 513 1.6 757 2.2
Prior residency and participation (using information from R1 and R2)
Previously participated, known HIV positive 2,526 4.1 5,696 8.6 /1 /
Previously participated, tested HIV negative 20,669 33.7 26,027 39.5 / /
Previously participated, declined offer of HIV testing 6,482 10.6 7,035 10.7 / /
Previously resident, but did not previously participate 8,771 14.3 3,739 5.7 / /
Newly resident in area of community in R3 and/or<15 years during R2 22,954 37.4 23,399 35.5 / /
1The”/” symbol indicates information not available for SA study communities.
Abbreviations: R1, Round 1; R2, Round 2; R3, Round 3; SA, South Africa
https://doi.org/10.1371/journal.pmed.1003067.t001
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participated in R3 in SA communities was lower than in Zambian communities, at 56%
(17,813/32,095) overall. In both countries, the participation rate was highest among young
men (18–24 years) and those�60 years.
For women in Zambian communities in R3, participation was very high across the age
range and was 86% (56,345/65,896) overall, consistent with findings in R1 and R2 (Fig 2).
Among all women who were resident in R3, 92% participated in one of R1–R3. The percentage
of women who participated in R3 in SA communities was lower than in Zambian communi-
ties, at 71% (24,461/34,514) overall, with relatively little variation by age group.
Arm A: Knowledge of HIV status among individuals who participated in
intervention
In Zambian communities, knowledge of HIV status following participation in the intervention
was very high in R3, at 90% for both men (37,330/41,332) and women (50,432/56,345). It was
Fig 2. Arm A: Participation in the PopART intervention, Zambian communities R1–R3, and SA communities R3, by sex and age group. R1, Round 1; R2, Round 2;
R3, Round 3; SA, South Africa.
https://doi.org/10.1371/journal.pmed.1003067.g002
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higher than in R2, following which 83% of men and 86% of women knew their HIV status, due
to higher uptake of the offer of HIV testing in R3 (Fig 3). In R3, it was high across the age
range 15–54 years for men and 15–44 years for women, and for individuals in all categories of
prior participation and residency except for those who had previously participated in the inter-
vention but never previously accepted the offer of HIV testing (S2 Fig).
In SA communities, knowledge of HIV status following participation in the intervention
in R3 was also high, though lower than in Zambian communities, at 78% (13,815/17,813)
for men and 85% (20,718/24,461) for women, with relatively little variation by age group (Fig 3).
Arm A: Individuals known by the CHiPs to be HIV positive, and
individuals newly diagnosed with HIV, among all who participated in the
intervention
In Zambian communities, the percentage of men who self-reported they were HIV positive in
R3 was similar to R2, both overall at 7.1% and by age group (Fig 4). The percentage who were
Fig 3. Arm A: Knowledge of HIV status following participation in the PopART intervention, Zambian communities R1–R3, and SA communities R3, by sex and
age group. R1, Round 1; R2, Round 2; R3, Round 3; SA, South Africa.
https://doi.org/10.1371/journal.pmed.1003067.g003
PLOS MEDICINE HIV testing and treatment coverage after 4 years of the HPTN 071 trial
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003067 April 2, 2020 11 / 30
newly diagnosed with HIV was slightly lower than in R2, at 1.7%. The overall percentage of
men who were known to be HIV positive following the R3 visit was 8.8%, slightly lower than
following R2.
In SA communities in R3, the percentage of men who self-reported they were HIV positive
was 6.7%, while the percentage who were newly diagnosed with HIV was relatively low across
the age range and 1.4% overall. The overall percentage of men who were known to be HIV pos-
itive following the R3 visit was slightly lower than in Zambian communities, at 8.1%.
For women in Zambian communities, the percentage who self-reported they were HIV pos-
itive was slightly higher in R3 than R2, at 13.7%; the percentage who were newly diagnosed
with HIV in R3 was slightly lower in R3 than R2, at 2.6%; and the overall percentage who were
known to be HIV positive was slightly higher in R3 than R2, at 16.3% (Fig 4). The pattern in
SA communities in R3 was similar to this, with overall 17.4% of women known to be HIV pos-
itive following R3.
Fig 4. Arm A: Self-report of HIV-positive status, new HIV-positive diagnosis, and total known to be HIV positive, as a percentage of individuals who participated
in the intervention; and the percentage of known HIV-positive individuals who were newly diagnosed HIV positive. Zambian communities R1–R3 and SA
communities R3, by sex and age group. R1, Round 1; R2, Round 2; R3, Round 3; SA, South Africa.
https://doi.org/10.1371/journal.pmed.1003067.g004
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The percentage of “known HIV-positive” individuals who were newly diagnosed was much
higher in younger than older individuals in both Zambian and SA communities, peaking
among 20- to 29-year-old men and 15- to 24-year-old women (Fig 4).
Arm A: Estimated HIV prevalence among participants and the total
population
Our estimates of HIV prevalence among participants of R3 followed the same age pattern
as for “known HIV-positive” prevalence and were slightly higher (S3 Fig). With extrapola-
tion to the total population (and thus its age structure), among men overall HIV preva-
lence was slightly higher than among participants, whereas among women it was slightly
lower.
Age-specific estimates of HIV prevalence, among participants and with extrapolation to the
total population, were slightly higher in R2 and R3 in Zambian communities, compared with
R1, but broadly the estimates were consistent across rounds and followed the same age pattern.
The peak HIV prevalence was among men aged 40 to 49 years (approximately 21%) and
women aged 35 to 44 years (approximately 31%), across rounds in Zambian communities and
in R3 in SA communities.
These estimates of HIV prevalence were used to calculate the denominator for estimates of
coverage against the first 90 target, at the start and end of each round.
Arm A: Knowledge of HIV-positive status (“first 90”) among participants,
and the total population (“central” estimates)
In Zambian communities, the estimated percentage of HIV-positive individuals who knew
their HIV-positive status progressively increased across R1–R3 (Table 2). Among individuals
who participated in the intervention in a particular round, the overall percentage of HIV-posi-
tive men who knew their HIV-positive status at the start of the round increased from 52% in
R1 to 78% at the start of R3, and by the end of R3 to 97%; figures for women were slightly
higher (Table 2, S4 Fig). With extrapolation to the total population, the “start-of-round” esti-
mates were similar to those among participants, but the “end-of-round” estimates were lower.
By the end of R3 in Zambian communities, an estimated 87% of HIV-positive men and 94% of
HIV-positive women knew their HIV-positive status (Fig 5), 92% overall, and the first 90 target
was met or close to being met across the age range (Fig 6).
Progress toward the first 90 target across R1–R3 in Zambian communities was slowed by
the high level of in-migration to, and out-migration from, each CHiP zone (Table 1), which
resulted in “start-of-round” estimates of coverage being lower than what had been estimated
for the end of the previous round (Fig 5). Among men who were newly resident in the zone in
which they were living in R3, overall an estimated 57% knew their HIV-positive status at the
start of the round compared with 91% among those who participated in the intervention in R1
and/or R2 and 66% among those who were previously resident in the same zone but did not
participate in the intervention in R1 or R2 (Table 3). The corresponding figures among
women were 65%, 91%, and 77%. These overall differences were also seen across the age range
(S5 Fig).
In SA communities, coverage against the first 90 target was high at the start of R3, with
overall estimates of 77% for HIV-positive men and 88% for HIV-positive women, and higher
by the end of R3 with overall estimates of 86% for HIV-positive men and 95% for HIV-positive
women (Table 2, Fig 5). Coverage was high across the age range but relatively lower among
HIV-positive men aged 20 to 29 years (Fig 6).
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Table 2. Arm A: Estimates of the percentage of HIV-positive individuals who knew their HIV-positive status (first 90), the percentage on ART among individuals
who knew their HIV-positive status (second 90), and the percentage on ART among all HIV-positive individuals (ART coverage).
Estimated HIV
+ individuals/
population
First 90 (%) Second 90 (%) ART coverage (%)
n/N % Immediately before
annual round visit
Immediately after
annual round visit
Immediately after
annual round visit
By end of
round
Immediately before
annual round visit
By end of
round
Participants in the
intervention
Zambia, men
R1 4,662/
45,399
10.3 52 89 47 72 42 64
R2 3,705/
35,888
10.3 71 94 64 80 60 75
R3 3,736/
41,332
9.0 78 97 73 85 71 83
Zambia, women
R1 9,499/
55,703
17.1 56 92 50 72 45 66
R2 8,515/
52,210
16.3 76 96 69 81 65 77
R3 9,395/
56,345
16.7 82 97 77 89 75 87
SA
Men, R3 1,557/
17,813
8.7 77 93 70 84 65 78
Women, R3 4,366/
24,461
17.8 88 97 82 92 80 90
Extrapolated to
total population
Zambia, men
R1 6,649/
61,606
10.8 52 78 54 74 42 57
R2 6,521/
61,332
10.6 67 79 71 81 56 65
R3 6,244/
64,704
9.7 75 87 79 88 69 76
Zambia, women
R1 11,037/
64,305
17.2 56 87 53 73 46 64
R2 10,690/
66,106
16.2 75 91 71 82 65 75
R3 11,418/
69,458
16.4 82 94 79 90 75 84
SA
Men, R3 3,088/
34,245
9.0 77 86 77 85 66 72
Women, R3 6,443/
36,859
17.5 88 95 84 92 80 87
Figures in bold are those to which particular attention is drawn in the text.
Abbreviations: ART, antiretroviral therapy; R1, Round 1; R2, Round 2; R3, Round 3
https://doi.org/10.1371/journal.pmed.1003067.t002
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Arm A: ART uptake among individuals who knew their HIV-positive status
(“second 90”), among participants and the total population (“central”
estimates”)
In Zambian communities, the overall percentage who were on ART among HIV-positive men
who knew their HIV-positive status immediately following participation in a particular round
increased from 47% in R1 to 73% at the start of R3, and by the end of R3 to 85%; figures for
women were approximately 4% higher (Table 2, S6 Fig).
With extrapolation to the total population, the “immediately-after-start-of-round” esti-
mates were higher than among participants (due to the conservative assumption that zero non-
participants were newly diagnosed with HIV during the round, so a new “gap” between
knowledge of HIV-positive status and treatment uptake was not created among nonpartici-
pants), and the “end-of-round” estimates were similar. By the end of R3, overall an estimated
88% of men and 90% of women were on ART among those who knew their HIV-positive
Fig 5. Arm A: Estimates of coverage against the first and second 90 targets, by sex, country, and round (with extrapolation to the total population). R1, Round 1; R2,
Round 2; R3, Round 3.
https://doi.org/10.1371/journal.pmed.1003067.g005
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status (Table 2, Fig 5), and 89% overall. The second 90 target was furthest from being met
among younger men (age 18–34 years) and women (age 15–24 years) (Fig 7). As with the first
90, progress toward the second 90 target across R1–R3 in Zambian communities was slowed
by the high level of population turnover within each CHiP zone (Table 3).
In SA communities, coverage against the second 90 target was high at the start of R3—with
overall estimates of 77% for HIV-positive men and 84% for HIV-positive women—and higher
by the end of R3 with overall estimates of 85% for HIV-positive men and 92% for HIV-positive
women (Table 2, Fig 5). Coverage was high across the age range but relatively lower among
HIV-positive men aged 18 to 34 years (Fig 7).
Arm A: ART coverage in the total population of HIV-positive individuals
(“central” estimates)
There was a progressive increase in estimated ART coverage among all HIV-positive individu-
als in the population (regardless of knowledge of their HIV-positive status) in Zambian
Fig 6. Arm A: Estimates of coverage against the first 90 target, Zambian communities R1–R3, and SA communities R3, by sex and age group (with extrapolation to
the total population). R1, Round 1; R2, Round 2; R3, Round 3; SA, South Africa.
https://doi.org/10.1371/journal.pmed.1003067.g006
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communities across 3 rounds of intervention (Table 2). Among HIV-positive men, estimated
ART coverage increased from 42% at the start of R1 to 69% at the start of R3, and to 76% by
the end of R3. Among HIV-positive women, estimated ART coverage increased from 46% at
the start of R1 to 75% at the start of R3, and to 84% by the end of R3. Overall, across HIV-posi-
tive men and women, estimated ART coverage was 82% by the end of R3.
Table 3. Arm A, Zambian communities R3: Estimates of the percentage of HIV-positive individuals who knew their HIV-positive status (first 90), the percentage
on ART among individuals who knew their HIV-positive status (second 90), and the percentage on ART among all HIV-positive individuals (ART coverage), by
prior residency and prior participation in the intervention in R1–R2.
Estimated
HIV
+ individuals/
population
First 90 (%) Second 90 (%) ART coverage (%)
n/N % Immediately before
annual round visit
Immediately after
annual round visit
Immediately after
annual round visit
By end of
round
Immediately before
annual round visit
By end of
round
Participants in the
intervention
Men
Participated in R1 and/or R2 2,276/
23,308
9.8 91 99 83 89 81 88
Resident in R1 and/or R2,
did not participate in either
round
261/
3,669
7.1 67 95 65 79 61 75
Newly resident in CHiP zone
in R3
1,199/
14,355
8.4 56 96 55 79 53 76
Women
Participated in R1 and/or R2 6,079/
34,547
17.6 92 98 84 91 82 89
Resident in R1 and/or R2,
did not participate in either
round
211/
1,963
10.7 76 95 77 89 73 85
Newly resident in CHiP zone
in R3
3,105/
19,835
15.7 64 96 64 84 61 81
Extrapolated to total
population
Men
Participated in R1 and/or R2 3,173/
31,273
10.1 91 96 84 89 81 86
Resident in R1 and/or R2,
did not participate in either
round
771/
9,236
8.3 66 76 81 87 62 66
Newly resident in CHiP zone
in R3
2,300/
24,195
9.5 57 78 69 85 54 66
Women
Participated in R1 and/or R2 7,091/
40,841
17.4 91 97 85 91 82 88
Resident in R1 and/or R2,
did not participate in either
round
450/
3,941
11.4 77 86 87 93 74 80
Newly resident in CHiP zone
in R3
3,877/
24,676
15.7 65 90 69 86 62 78
Figures in bold are those to which particular attention is drawn in the text.
Abbreviations: ART, antiretroviral therapy; CHiP, community HIV care provider; R1, Round 1; R2, Round 2; R3, Round 3
https://doi.org/10.1371/journal.pmed.1003067.t003
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Population turnover slowed the increase in ART coverage across rounds in Zambian com-
munities (Table 3). For example, at the start of R3, an estimated 54% of HIV-positive men
were on ART among those who were newly resident in the zone in which they were living in
R3. This compared with 81% among those who participated in the intervention in R1 and/or
R2, and 62% among those who were previously resident but had not previously participated in
the intervention (Table 3).
In SA communities, estimated ART coverage was 72% in HIV-positive men (slightly lower
than in Zambian communities) and 87% in HIV-positive women (slightly higher than in Zam-
bian communities) by the end of R3 (Table 2) and overall was 82%.
Arm A, R3: Sensitivity analyses of estimates of knowledge of HIV-positive
status and ART uptake in total population
Estimates of ART coverage, and of coverage against the first and second 90 targets, were not
sensitive to different assumptions about individuals who participated in the PopART
Fig 7. Arm A: Estimates of coverage against the second 90 target, Zambian communities R1–R3, and SA communities R3, by sex and age group (with extrapolation
to the total population). R1, Round 1; R2, Round 2; R3, Round 3; SA, South Africa.
https://doi.org/10.1371/journal.pmed.1003067.g007
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intervention but whose HIV status was not known to the CHiPs (Table 4). However, they were
sensitive to different assumptions about individuals who were resident but did not participate
in the intervention during R3; ART coverage estimates were approximately 9% to 15% lower
among men and approximately 5% to 13% lower among women, in “conservative” sensitivity
analyses that assumed lower testing and treatment coverage among individuals who did not
participate in the PopART intervention compared with our “central” assumptions (Table 4).
Table 4. Arm A, R3: Sensitivity analysis of estimates of ART coverage and estimates of coverage against the first and second 90 targets: Example “conservative”
scenarios.
Men
Zambia SA
First 90 (%) Second 90 (%) ART coverage (%) First 90 (%) Second 90 (%) ART coverage (%)
Immediately
before
annual
round
Immediately
after annual
round
Immediately
after annual
round
By
end of
round
Immediately
before
annual
round
By
end of
round
Immediately
before
annual
round
Immediately
after annual
round
Immediately
after annual
round
By
end of
round
Immediately
before
annual
round
By
end of
round
Central
estimate
75 87 79 88 69 76 77 86 77 85 66 72
Scenario
11
75 86 79 87 67 75 77 85 75 82 64 70
Scenario
22
71 82 72 81 60 67 70 77 67 76 52 58
Scenario
33
70 80 72 81 58 65 69 76 67 75 51 57
Women
Zambia SA
First 90 (%) Second 90 (%) ART coverage (%) First 90 (%) Second 90 (%) ART coverage (%)
Immediately
before
annual
round
Immediately
after annual
round
Immediately
after annual
round
By
end of
round
Immediately
before
annual
round
By
end of
round
Immediately
before
annual
round
Immediately
after annual
round
Immediately
after annual
round
By
end of
round
Immediately
before
annual
round
By
end of
round
Central
estimate
82 94 79 90 75 84 88 95 84 92 80 87
Scenario
11
81 93 79 89 74 83 88 94 84 91 79 86
Scenario
22
80 92 76 86 70 79 83 89 79 86 70 76
Scenario
33
79 91 76 86 67 78 82 87 78 85 68 74
1Scenario 1 = Among individuals who participated in the intervention in R3 but whose HIV status was not known to the CHiPs: HIV prevalence is twice as high as
among individuals who accepted the offer of HIV testing in R3, their knowledge of their HIV-positive status is half the “immediately prior to R3” value among
individuals whose HIV-positive status is known to CHIPs following R3, and their ART uptake is half the “immediately prior to R3” value among individuals who self-
reported they were HIV positive in R3.
2Scenario 2 = As for Scenario 1 for participants. For nonparticipants: HIV prevalence is assumed to be the same as among participants, knowledge of HIV-positive
status immediately prior to R3 is 0.8 times the value for participants, and ART uptake among individuals who know their HIV-positive status is 0.8 times the value for
participants.
3Scenario 3 = As for Scenario 2, except that HIV prevalence is assumed to be 1.25 times the value for participants. This is the “worst-case” scenario, among those
considered in our sensitivity analyses.
All assumptions are made within strata defined by every combination of sex, community, age group, and (for Zambia) prior residency and participation in the
intervention.
Abbreviations: ART, antiretroviral therapy; CHiP, community HIV care provider; R3, Round 3
https://doi.org/10.1371/journal.pmed.1003067.t004
PLOS MEDICINE HIV testing and treatment coverage after 4 years of the HPTN 071 trial
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003067 April 2, 2020 19 / 30
Arm A: Time to ART initiation after CHiP referral to HIV care
In R3, by 31 October 2017, 2,554 HIV-positive individuals had been referred to HIV care
in Zambian communities and 928 in SA communities. Most were referred after testing HIV pos-
itive in R3–75% in Zambia and 68% in SA—and the rest self-reported they were HIV positive.
The median time to ART initiation after referral to HIV care was approximately 3 months in
both countries, considerably shorter than in previous rounds (P< 0.001), and by 12 months
after referral an estimated approximately 70% had initiated ART (Fig 8). The shortening of the
time to ART initiation over R1–R3 was seen overall, and for both men and women [17].
Comparison of Arm A with Arm B communities
Overall, and with stratification by country and round and sex and age group, all measures of
intervention coverage were similar in Arm A and Arm B communities (S7–S12 Figs show the
equivalent figures to those provided for Arm A in Figs 2–4 and 6–8).
Fig 8. Arm A: Time from CHiP referral to ART initiation among individuals referred to HIV care, by country and round of referral. ART, antiretroviral therapy;
CHiP, community HIV care provider; R1, Round 1; R2, Round 2; R3, Round 3; SA, South Africa.
https://doi.org/10.1371/journal.pmed.1003067.g008
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Coverage against the first and second 90 targets in Arm B is summarised in Fig 9, for direct
comparison with Arm A as summarised in Fig 5. In Fig 10, ART coverage estimates for Arm A
and Arm B are compared by country, round, and sex; if anything, coverage was slightly lower
in Arm B than in Arm A, but the 2 trial arms had similar trajectories across rounds in Zambian
communities and similar end-of-intervention coverage in SA communities. A formal compari-
son between Arm A and Arm B for these 3 coverage measures at the end of R3—based on 14
community-level summaries and applying the approach to trial arm comparisons that was set
out in the HPTN 071 statistical analysis plan [15]—showed that there was no statistical evi-
dence of a difference between the 2 trial arms (S1, S2 and S3 Tables).
Estimates of coverage against the third 90 target from the population
cohort study
Estimates of coverage against the third 90 target were at or close to 90% in Zambian communi-
ties, across men and women and Arm A and Arm B (Table 5). In SA communities, coverage
Fig 9. Arm B: Estimates of coverage against the first and second 90 targets, by sex, country, and round (with extrapolation to the total population). R1, Round 1; R2,
Round 2; R3, Round 3.
https://doi.org/10.1371/journal.pmed.1003067.g009
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against the 3rd 90 target was approximately 85% in women and in the range of approximately
80% to 90% for men. Overall, estimates were similar in Arm A and Arm B.
Fig 10. Arm A and Arm B: ART coverage estimates, by trial arm, sex, country, and round (with extrapolation to the total population). ART, antiretroviral therapy;
R1, Round 1; R2, Round 2; R3, Round 3.
https://doi.org/10.1371/journal.pmed.1003067.g010
Table 5. Viral suppression among HIV-positive individuals who self-reported they had taken ART in the previous
1 month, from the 24-month follow-up (mid-2016 to mid-2017) of the population cohort study.
Arm A Arm B
n/N1 % n/N1 %
Zambia, men 84/98 85.7 80/89 89.9
Zambia, women 615/674 91.2 608/669 90.9
SA, men 25/28 89.3 31/39 79.5
SA, women 286/337 84.9 308/364 84.6
1n/N = number virally suppressed/total HIV-positive and self-reported taking ART in the previous 1 month.
Abbreviation: ART, antiretroviral therapy
https://doi.org/10.1371/journal.pmed.1003067.t005
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Discussion
The HPTN 071 (PopART) trial, implemented in urban/peri-urban communities in Zambia
and SA during 2014–2018, aimed to establish whether universal testing and universal treat-
ment for HIV could reduce population-level HIV incidence in a generalised HIV epidemic. To
be effective, the PopART intervention needed to achieve high rates of HIV testing and treat-
ment coverage across the community, and so a key secondary aim of the study was to learn
whether this goal could be attained. We found that high levels of HIV testing and treatment
coverage were achieved in communities that received the PopART UTT intervention, espe-
cially among women, and the cumulative 90–90 target of 81% ART coverage was met overall.
This took 4 years, to the end of the study, by which time approximately 95% of HIV-positive
women and approximately 85% of HIV-positive men knew their HIV status; among these
individuals, approximately 90% of women and approximately 85% of men were on ART.
Among all HIV-positive individuals, regardless of knowledge of their HIV-positive status,
ART coverage was approximately 85% in women and approximately 75% in men in both the
Zambian and SA communities, around 10% higher than after the first 2 years of the interven-
tion and up from around 45% at the start of the study.
Progress toward reaching high testing and treatment coverage was slowed by high rates of
mobility and in-migration among both men and women, with mobile individuals and in-
migrants having lower knowledge of HIV-positive status and ART coverage than “stable” resi-
dents, as reported previously [7] and also found in the ANRS 12249 TasP trial [18]. The way in
which the PopART intervention was delivered through “rounds” of visits to every household
meant that it was effective in identifying and including newly resident individuals, but only
with a delay. Progress was also slowed by the relative difficulty of contacting men at home
[7,19–23], which persisted throughout the study. Service coverage among men and mobile
individuals might have been accelerated if CHiPs had been able to offer services outside of a
household setting more often.
The main gap in coverage against the first and second of the 90-90-90 targets that remained
after 4 years of intervention was among men aged 18 to 34 years and women aged 15 to 24
years, consistent with findings from the SEARCH and BCPP/YaTsie studies [4,5]. In both
groups, coverage progressively increased, and participation in the intervention, testing uptake
among participants, and the time from CHiP referral to ART initiation were similar to or
higher than among individuals aged 35 to 54 years. The reason for the remaining postinterven-
tion gap was that the proportion of HIV-positive individuals who knew their HIV-positive sta-
tus “pre-intervention” and at the start of each round was much lower for younger than older
individuals. This reflected fewer prior opportunities for facility-based HIV testing, relatively
high HIV incidence rates compared with HIV prevalence, and relatively high mobility and in-
migration rates. The “pre-intervention” gap among younger individuals might be reduced by
making facility-based services more “youth friendly,” and steps toward this were taken during
the last year of intervention as part of the nested “PopART-for-Youth” (P-ART-Y) study. The
provision of HIV self-testing could also contribute [14,24–26].
Participation in the PopART intervention, and the uptake of HIV testing among partici-
pants, increased between the second and third rounds in Zambia. This showed that service
uptake can improve with time and accrued experience, rather than worsen with fatigue, when
a community increasingly values the services that are being offered and trusts the individuals
who are providing them. On the other hand, a proportion of individuals never participated in
the intervention despite CHiPs being continuously present in the community for 4 years, and
even among participants a proportion repeatedly declined the offer of HIV testing. These fac-
tors placed an upper limit on the testing and treatment coverage that could be achieved. In the
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future, it is possible that more service provision in the community outside a household setting
and the option of HIV self-testing might reach some previously unreached individuals [14,24–
27].
In the first round of intervention, the time between referral of an HIV-positive individual
to HIV care by CHiPs and ART initiation was much slower than originally targeted, slowing
progress toward high treatment coverage. However, by the third round of intervention, the
median time from CHiP referral to ART initiation had been shortened from approximately 10
months in the first round to approximately 3 months. This reflected increased trust in the
CHiPs with time, as well as the success of the various strategies that were implemented to facil-
itate linkage to HIV care—tailored according to the needs of each individual—during the
entirety of the second and third rounds of intervention. At the same time, it confirmed
earlier findings that a proportion of HIV-positive individuals need and/or wish to take a
period of time from when they first learn their HIV-positive status to when they link to HIV
care [8].
Our finding that the first and second of the 90-90-90 targets can be attained through several
years of community-wide delivery of a combination HIV prevention package that includes
universal testing and facilitated linkage to universal treatment is consistent with previously
reported findings [4,5]. In the SEARCH study in rural Uganda and Kenya, HIV testing services
were delivered annually from a central community location for a period of several weeks, sup-
plemented by household visits. In the BCPP/YaTsie study in Botswana, door-to-door HIV test-
ing services were delivered annually, supplemented with community provision in a
nonhousehold setting. Other studies have also demonstrated the potential of community-wide
delivery of home-based testing and support for linkage to care to achieve high testing and
treatment coverage prior to guidelines changing to recommend universal ART, for example,
in 2 communities in Uganda and SA [28]. At a national level, as of 2017, Malawi and eSwatini
had come close to achieving the 90-90-90 targets through the expansion of community-based
HIV testing services alongside facility-based testing at multiple clinical service points, as well
as strengthened support for linkage to HIV care and ART initiation following testing [29–31].
Taken in this context, our study extends the generalisability of the finding that 90-90-90 can be
achieved through persistent delivery of UTT services, in particular to urban settings and to 2
additional countries.
There were several limitations to our study. First, our estimates of testing and treatment
coverage for all men (as opposed to men who participated in the PopART intervention) relied
on considerable extrapolation because in each round approximately one-third of men did not
participate. We may have overestimated what was achieved for ART coverage among men by
up to around 10% in absolute terms. Second, our findings are for a service delivery model that
was relatively intensive, with 2 CHiPs for every 500 households and approximately 1,000 to
1,500 adults. Although the cost per resident aged�15 years was relatively modest at approxi-
mately $6 to $8 per year, the PopART intervention might need to be adapted and/or stream-
lined to be more affordable for programmatic delivery on a large scale. Third, we did not have
comparable data on testing and treatment coverage from the “standard-of-care” trial arm
(Arm C), because in Arm C communities, there were no CHiPs delivering the PopART inter-
vention. The trial population cohort study was conducted in all 21 study communities but
could not provide unbiased estimates of testing and treatment coverage because all partici-
pants were offered rapid HIV testing at every follow-up survey. Additionally, information on
viral suppression was not collected by CHiPs as part of intervention service delivery, and for
most of the study period, viral load testing was not routine in the study community clinics in
Zambia. Although it was a limitation of our data that ART uptake was self-reported, a strength
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was that, among those who self-reported that they were on ART, a high percentage (approxi-
mately 80%) showed their ART card to CHiPs.
While we focused our attention on analysis of findings from the “full” PopART UTT inter-
vention arm over 4 years of intervention delivery, we also showed that achievements were sim-
ilar in the “intermediate” intervention arm. At trial start, the 2 trial arms differed only in the
CD4 threshold used for ART eligibility; within 6–12 months of study start, the difference
diminished when the CD4 threshold for ART eligibility was raised to 500 cells/mm3 in the
intermediate intervention arm, and it was then eliminated when universal ART became stan-
dard of care during the last 18 months of intervention delivery. This meant that the 2 trial
arms were very similar for ART eligibility for most of the 4-year intervention-delivery period,
and the time when they differed most—the first year of the study—was also when the time
from CHiP referral to linkage to HIV care was relatively slow across all study communities.
From our comparison of testing and treatment coverage in Arms A and B, there was no evi-
dence of a differential that could explain the larger reduction in HIV incidence that was
observed in Arm B compared with Arm A communities. Other possible explanations being
explored include differentials in migration, partners from outside the study community, and
behaviour change.
Conclusion
Our study showed that very high HIV testing and treatment coverage can be achieved over
several years through persistent delivery of universal testing, facilitated linkage to HIV care,
and universal treatment services. Our findings are consistent with previously reported findings
from southern and east Africa, extending their generalisability to urban settings with high
rates of in-migration and mobility and to Zambia and SA.
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